Medicine subdivision track adds new products!Vaccine ETF and Chinese Medicine ETF are all here

Recently, there are new ETFs approved by the Medicine Subtraction Circuit. According to reporters, Huatai Berry, Cathay Fund, and Wells Fund have 1 vaccine theme ETF approved. In addition, Huatai Berry, Yinhua Fund, Huitianfu Fund, and Penghua Fund also have 1 Chinese medicine ETF ETF respectively Approved.

3 vaccines ETF approval

Recently, the pharmaceutical sector has rebounded significantly. Since June 6, the SCR pharmaceutical index has risen by 19.01%. Many pharmaceutical -themed funds have also obviously "returning blood".

According to the latest understanding of the reporter, new products have been approved in the medical segment track. Among them, Huatai Berry, Cathay Fund, and Wells Fund have 1 vaccine theme ETF approved.

It is reported that the State Cover Vaccine and Biotechnology Index are representative listed companies that involve vaccines and biotechnology industries from the Shanghai and Shenzhen market as index samples to reflect the overall performance of the securities of vaccine and biotechnology listed companies.

Cathay Fund said that under the influence of the new crown epidemic, the emergency vaccine market of sudden infectious diseases rose rapidly. The awareness of the whole people has greatly improved the consciousness of vaccination, not only limited to sudden infectious diseases such as new crown vaccines, vaccines such as HPV and shingles that are not included in the state of immunization planning are gradually valued by the whole people. At the same time, the vaccine at the same time vaccine Investment activities have risen rapidly, and a large amount of capital influx, and large -scale vaccine companies in the local area have been listed on the market to achieve industrial upgrading. Generally speaking, the relevant industrial market demand is large, and the investment value of vaccines and biotechnology tracks is prominent.

Huatai Berry Fund also said that vaccine, as an important part of biotechnology, has become more important with the improvement of residents' rigid demand for life health and the gradual improvement of the construction of the public health system. In the future, the scale of the global vaccine market is expected to continue to expand, and vaccines and biotechnology tracks will have a long -term significant strategic significance and investment value.

4 Chinese medicine ETF is coming too

In addition, the Chinese medicine ETF was recently approved. According to reporters, Huatai Berry, Yinhua Fund, Huitianfu Fund, and Penghua Fund also had one Chinese medicine ETF approved.

Among them, the Chinese medicine ETF of Huatai Berry Fund, Yinhua Fund, and Huitianfu Fund will be released on the Shanghai Stock Exchange.

The Shanghai Stock Exchange stated that this is an important measure for the implementation of the Party Central Committee and the State Council's relevant decision -making and deployment of the Party Central Committee and the State Council to help resist with epidemic and resume production. Since 2020, the Shanghai Stock Exchange has actively deployed the theme fund of anti -epidemic and promoted ETFs such as the development of vaccines, biomedicine, and online consumption. The scale of related products that have been listed is nearly 5 billion yuan.

Tan Hongxiang, director of the Investment Department of Huatai Berry Index, said, "The Chinese medicine industry has the advantages of policy support and low valuations. Related products are relatively scarce and have a large degree of distinction with existing biomedical products, which match the specific needs of investors. The special concept of traditional Chinese medicine in the "health fitness" is in line with the new trend of 'health -centric ". In the future, with the improvement of industry governance, the supply of high -quality products and services has increased. And the disclosure of major achievements in theoretical research, Chinese medicine is expected to get more and more support and recognition. "

Zhang Yuxiang, a Penghua Fund, pointed out: "The early Chinese medicine sector was in the confusion and dilemma of the bottom of the valley for a long time. In 2022, it is expected to usher in the reversal of the predicament. In recent years, the state has strongly supported the development of traditional Chinese medicine. The criteria for approval are also constantly standardized, and the supply -side reforms ushered in incremental logic; in the context of the overall pharmaceutical sector valuation return, the traditional Chinese medicine sector is used as low valuation and policy -free ports. It is believed that the traditional Chinese medicine market has medium and long -term sustainability. Traditional Chinese medicine has the attributes of consumer goods and health products. The population of the country is aging, the medical and health needs of middle -aged and elderly people have increased day by day, residents' consumption upgrades, and the Chinese medicine industry has maintained growth. "

In fact, for ordinary investors, the field of vaccines and Chinese medicine is also a highly professional area. The industry competition pattern and technical route are also large uncertainty. Therefore, choosing index investment may also be a relatively stable choice. Approval can better meet investors' demand for such track products.

Daily Economic News

- END -